BREVICON 1/35 TABLETS (21-DAY PACK) 1 MG
NORETHINDRONE : 1 MG ETHINYL ESTRADIOL : 0.035 MG · DIN 02189054 · PFIZER CANADA ULC
Health Canada status: MARKETED
What is BREVICON 1/35 TABLETS (21-DAY PACK)?
BREVICON 1/35 TABLETS (21-DAY PACK) 1 MG contains NORETHINDRONE : 1 MG ETHINYL ESTRADIOL : 0.035 MG. It is listed in the Health Canada Drug Product Database under DIN 02189054, held by PFIZER CANADA ULC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 03-Feb-2009. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is BREVICON 1/35 TABLETS (21-DAY PACK) used for?
Prevention of pregnancy (oral contraceptive).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
What else is BREVICON 1/35 TABLETS (21-DAY PACK) called?
The same molecule, NORETHISTERONE AND ESTROGEN, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Primolut N | Latin | Australia, Bahrain |
| NORISTERAT | Latin | Morocco |
| AMINOR | Latin | Bahrain |
| Micro-Novum | Latin | South Africa |
| MILLIGYNON | Latin | Morocco |
| NORLUTEN | Latin | Morocco |
| PRIMOLUT-NOR | Latin | Morocco |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Product details and regulatory record
| DIN | 02189054 |
|---|---|
| Brand name | BREVICON 1/35 TABLETS (21-DAY PACK) |
| Generic / active ingredient | NORETHINDRONE : 1 MG ETHINYL ESTRADIOL : 0.035 MG |
| Manufacturer | PFIZER CANADA ULC |
| Strength | 1 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | G03AA05 NORETHISTERONE AND ESTROGEN |
| AHFS class | 68:12.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 03-Feb-2009 |
| Original market date | 1996-08-14 00:00:00 |
How is this product identified?
Purchase orders, customs paperwork and tender documents each ask for a different identifier, and a DIN written without its leading zeros is the single most common reason an order line fails to match. Every form Nexara accepts for this product is listed here.
| DIN (8-digit, as used in Nexara ordering) | 02189054 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2189054 |
| Brand name | BREVICON 1/35 TABLETS (21-DAY PACK) |
| Active ingredient / INN | NORETHINDRONE : 1 MG ETHINYL ESTRADIOL : 0.035 MG |
| ATC code | G03AA05 |
| ATC anatomical main group | G — Genito-urinary system and sex hormones |
| ATC therapeutic subgroup | G03 |
| AHFS class | 68:12.00 |
| Health Canada schedule | Prescription |
| Biosimilar biologic | No |
| Market authorization holder | PFIZER CANADA ULC |
How is it administered?
One tablet daily at the same time. 21-day pack: 21 days on, 7 days off. 28-day pack: 21 active tablets followed by 7 inactive tablets. Start on Day 1, Day 5, or first Sunday of cycle.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly stated in provided text (standard section 11 header present but details truncated).
How is it supplied?
21-day and 28-day dispensers. 28-day dispensers contain 21 active and 7 inactive tablets.
Which pack is which?
| Strength on the label | 1 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
| Packaging as described in the monograph | 21-day and 28-day dispensers. 28-day dispensers contain 21 active and 7 inactive tablets. |
| Storage | Not explicitly stated in provided text (standard section 11 header present but details truncated). |
One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced. Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Contraindications
Thrombophlebitis, thromboembolic disorders, CAD, MI, cerebrovascular disease, liver disease/tumours, breast/endometrial cancer, undiagnosed vaginal bleeding, pregnancy, smokers over 35.
Warnings and precautions
Cigarette smoking increases risk of serious cardiovascular effects, especially over age 35. Does not protect against STDs/HIV. Discontinue if thromboembolic symptoms occur.
What can be used instead?
Other Canadian products sharing ATC code G03AA05 NORETHISTERONE AND ESTROGEN. 6 of 25 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| BREVICON 0.5/35 TABLETS (21-DAY PACK) | 0.5 MG | TABLET | PFIZER CANADA ULC | MARKETED | DIN 02187086 |
| BREVICON 0.5/35 TABLETS (28-DAY PACK) | .5 MG | TABLET | PFIZER CANADA ULC | MARKETED | DIN 02187094 |
| BREVICON 1/35 TABLETS (28-DAY PACK) | 1 MG | TABLET | PFIZER CANADA ULC | MARKETED | DIN 02189062 |
| SELECT 1/35 (21-DAY) | 1.0 MG | TABLET | PFIZER CANADA ULC | MARKETED | DIN 02197502 |
| SELECT 1/35 (28-DAY) | 1.0 MG | TABLET | PFIZER CANADA ULC | MARKETED | DIN 02199297 |
| BREVICON 0.5/35 21 TAB | .035 MG | TABLET | SYNTEX INC. | CANCELLED POST MARKET | DIN 00373265 |
| BREVICON 0.5/35 28 TAB | .5 MG | TABLET | SYNTEX INC. | CANCELLED POST MARKET | DIN 00373273 |
| BREVICON 1/35 21 TAB | .035 MG | TABLET | SYNTEX INC. | CANCELLED POST MARKET | DIN 00531006 |
| BREVICON 1/35 28 TAB | .035 MG | TABLET | SYNTEX INC. | CANCELLED POST MARKET | DIN 00531014 |
| GENERESS | 0.025 MG | TABLET (CHEWABLE) | ALLERGAN INC | CANCELLED PRE MARKET | DIN 02435659 |
Who else supplies NORETHISTERONE AND ESTROGEN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. NORETHISTERONE AND ESTROGEN appears in 14 registered pack listings across 8 markets, published on 7 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How much does NORETHISTERONE AND ESTROGEN cost around the world?
NORETHISTERONE AND ESTROGEN is listed on 6 national price registers Nexara tracks, across 15 pack listings published on 6 different price bases. What each country publishes is set out below.
| Market | What that country publishes | Brands listed | Pack listings | As of |
|---|---|---|---|---|
| Australia | ex-manufacturer | 4 | 5 | 08 Sep 2026 |
| Morocco | PPV (public price) | 4 | 5 | 05 Sep 2026 |
| Bahrain | retail (max) | 2 | 2 | 01 Sep 2026 |
| United Kingdom | hospital | 1 | 1 | 31 Aug 2026 |
| Saudi Arabia | public | 1 | 1 | 01 Sep 2026 |
| South Africa | single exit price | 1 | 1 | 01 Sep 2026 |
Why there are no figures here. These bases are not comparable. A Brazilian ex-factory ceiling, a Belgian pharmacy public price and a Japanese reimbursement rate answer three different questions, and none of them is what a product lands in Canada for. Putting them side by side would mislead in both directions, so Nexara publishes where a molecule is listed and on what basis, and quotes the delivered Canadian price per order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.